Type 2 Diabetes Mellitus: The Impact on Colorectal Adenoma Risk in Women

Elwing, Jill E.; Gao, Feng; Davidson, Nicholas O.; Early, Dayna S.
August 2006
American Journal of Gastroenterology;Aug2006, Vol. 101 Issue 8, p1866
Academic Journal
OBJECTIVES: Increased risk for colorectal cancer (CRC) has been associated with type 2 diabetes. Despite several studies linking insulin resistance to increased CRC risk, there are limited data on colorectal adenoma risk in diabetic women. We hypothesized that diabetic women would have increased rates of colorectal adenomas relative to a group of nondiabetic women. METHODS: Colorectal adenoma rates were determined in 100 estrogen-negative women with type 2 diabetes mellitus and compared with 500 nondiabetic, estrogen-negative controls. Adenomas were defined as any adenoma or advanced adenoma (villous or tubulovillous features, size >1 cm or high-grade dysplasia). A multivariate model including age, race, diabetes, hypertension, hypercholesterolemia, body mass index, and nonsteroidal anti-inflammatory drug status was used to determine the independent effects of diabetes on colorectal adenoma incidence. RESULTS: Diabetics as compared with nondiabetics had greater rates of any adenoma (37% vs 24%, p= 0.009) and advanced adenomas (14% vs 6%, p= 0.009). Two hundred forty-five obese subjects compared with 355 nonobese subjects had a higher rate of any adenoma (32% vs 22%, p= 0.001). Obese diabetics compared with nonobese, nondiabetics had greater rates of any adenoma (42% vs 23%, p≤ 0.001) and advanced adenomas (19% vs 7%, p≤ 0.001). Multivariate analysis showed that adenomas and advanced adenomas were independently predicted by diabetes ( p < 0.05) and adenomas by age. DISCUSSION: Women with type 2 diabetes mellitus had higher rates of colorectal adenomas as compared with lean and nondiabetic women. This finding adds to the evidence that type 2 diabetes is an important factor in the progression of the adenoma-carcinoma sequence.


Related Articles

  • Type 2 diabetes risk variants and colorectal cancer risk: the Multiethnic Cohort and PAGE studies. Cheng, Iona; Caberto, Christian P.; Lum-Jones, Annette; Seifried, Ann; Wilkens, Lynne R.; Schumacher, Fredrick R.; Monroe, Kristine R.; Unhee Lim; Tiirikainen, Maarit; Kolonel, Laurence N.; Henderson, Brian E.; Stram, Daniel O.; Haiman, Christopher A.; Marchand, Loïc Le // Gut;Dec2011, Vol. 60 Issue 12, p1703 

    Background: Diabetes has been positively associated with the risk of colorectal cancer. This study investigated whether recently established risk variants for diabetes also have effects on colorectal cancer. Methods: 19 single nucleotide repeats (SNPs) associated with type 2 diabetes in...

  • Prolonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes. Chin-Hsiao Tseng; Tseng, Chin-Hsiao // BMC Cancer;11/4/2015, Vol. 15, p1 

    Background: Human insulin is commonly used to treat hyperglycemia in patients with diabetes, but its potential link with female breast cancer is under debate. This study investigated whether human insulin use might be associated with breast cancer risk in Taiwanese women with type 2...

  • Cancer risk among patients with type 2 diabetes mellitus: a population-based prospective study in China. Wang, Meng; Hu, Ru-Ying; Wu, Hai-Bin; Pan, Jin; Gong, Wei-Wei; Guo, Li-Hua; Zhong, Jie-Ming; Fei, Fang-Rong; Yu, Min // Scientific Reports;6/19/2015, p11503 

    Evidence indicates an increased cancer risk among type 2 diabetes mellitus (T2DM) patients, yet studies in mainland China are scarce. Based on Diabetes Surveillance System linking to Cancer Surveillance System of Zhejiang Province in China, we explored the cancer risk among T2DM patients....

  • Cancer Incidence in Patients With Type 1 Diabetes Mellitus: A Population-Based Cohort Study in Sweden. Zendehdel, Kazem; Nyrén, Olof; Östenson, Claes-Göran; Adami, Hans-Olov; Ekbom, Anders; Weimin Ye // JNCI: Journal of the National Cancer Institute;12/3/2003, Vol. 95 Issue 23, p1797 

    Although patients with type 2 diabetes have elevated risks of liver, pancreatic, kidney, and endometrial cancer, little is known about the risk of cancer for patients with type 1 diabetes. We conducted a cohort study to examine cancer incidence among 29 187 patients in Sweden who were...

  • Candesartan and telmisartan may increase cancer risk.  // Reactions Weekly;7/16/2011, Issue 1360, p6 

    The article reports on a study which found that candesartan and telmisartan may possibly increase the risk of cancer in patients with type 2 diabetes mellitus (T2DM).

  • Mortality After Incident Cancer in People With and Without Type 2 Diabetes. Currie, Craig J.; Poole, Chris D.; Jenkins-Jones, Sara; Gale, Edwin A. M.; Johnson, Jeffrey A.; Morgan, Christopher Ll. // Diabetes Care;Feb2012, Vol. 35 Issue 2, p299 

    OBJECTIVE--Type 2 diabetes is associated with an increased risk of several types of cancer and with reduced survival after cancer diagnosis. We examined the hypotheses that survival after a diagnosis of solid-tumor cancer is reduced in those with diabetes when compared with those without...

  • Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Bansal, D; Bhansali, A; Kapil, G; Undela, K; Tiwari, P // Prostate Cancer & Prostatic Diseases;Jun2013, Vol. 16 Issue 2, p151 

    Background:Emerging evidence suggests that diabetes may increase the risk of cancers. However, available evidence on prostate cancer is conflicting. We therefore examined the association between Type 2 diabetes and risk of prostate cancer by conducting a detailed meta-analysis of all studies...

  • LDL levels may be linked to cancer risk in type 2 diabetes.  // Endocrine Today;10/10/2008, Vol. 6 Issue 18, p18 

    The article discusses research on the association of low density lipoproteins (LDL) with cancer risk in type 2 diabetes. Researchers said the relationship between LDL and cancer is represented by a V-shaped curve in patients with diabetes. They found that 270 patients developed cancer at a...

  • New Users of Metformin Are at Low Risk of Incident Cancer. Libby, Gillian; Donnelly, Louise A.; Donnan, Peter T.; Alessi, Dario R.; Morris, Andrew D.; Evans, Josie M. M. // Diabetes Care;Sep2009, Vol. 32 Issue 9, p1620 

    OBJECTIVE -- The antidiabetic properties of metformin are mediated through its ability to activate the AMP-activated protein kinase (AMPK). Activation of AMPK can suppress tumor formation and inhibit cell growth in addition to lowering blood glucose levels. We tested the hypothesis that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics